A Phase 2 interventional study of Everolimus and Letrozole in Postmenopausal Women, Locally Advanced Metastatic Breast Cancer and Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.
Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 36th largest by enrollment, is one of 3 that started in 2011, is one of 40 in phase 2, and was the 28th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
MedSIR · Sites in Austria, Brazil, Czechia and 6 more countries
Ages 18+
Fudan University · Sites in China
Ages 18–70 · Women only
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 17 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 55 across the 78 interventional studies. Of the 57 that completed or were terminated, 35 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 89th largest by enrollment of the 155 interventional ones that give a count, is one of 4 that started in 2011, is one of 39 in phase 2, and was the 72nd registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing everolimus in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT06382948Phase 3MedSIRElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 78 studies testing everolimus in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or Examestane.
There were no treatments specifically approved after recurrence or progression on AIs. Available options, based on common clinical practice and several treatment guidelines (e.g. NCCN treatment guidelines 2008), included fulvestrant.
Combining RAD001 with letrazole was a rational approach to the treatment of advanced Brest Cancer, offering the potential for inhibition of tumor cell growth\ proliferation and anti angiogenesis while at the same time potentially preventing the development of letrazole resistance.
Screening Period:
Postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer whose disease was refractory to hormonal therapy and had a documented recurrence or progression on last therapy for their breast cancer with either tamoxifen, anastrozole, letrozole, fulvestrant or exemestan were screened for eligibility within 28 days prior to treatment Day 1.
Treatment Period:
Patients started receiving everolimus (10 mg daily oral dose) combined with letrozole (2.5 mg daily oral dose) tablets from treatment Day 1. Study treatment continued until disease progression, intolerable toxicity or consent withdrawal. Dose adjustment (reduction, interruption or possible dose re-escalation to starting dose) could be done based on the safety findings. Tumor assessments were performed every 12 weeks until disease progression. In order to confirm response at least four weeks after first observation, additional scans to determine a complete response (CR) or partial response (PR) or stable disease (SD) were performed. Patients were followed for safety until 28 days after study treatment discontinuation.
Post Treatment Follow up for Survival:
Patients were followed for survival every 3 months for up to 3 years. Survival information could be obtained via phone and information was documented in the source documents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women with estrogen receptor positive locally advanced or breast cancer after documented recurrence or progression on Tamoxifen, Anastrozole or Examestane.
disease to hormonal therapy is defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.
Drug: Everolimus · Drug: Letrozole
Everolimus 10 mg (2 tablets of 5 mg) once daily
Also known as: RAD001
Letrozole 2.5 mg once daily
Percentage of Participants With Overall Response Rate (ORR)
Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. Only descriptive statistics.
Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 15 months
Median Time to Progression-Free Survival (PFS)
Progression Free Survival (PFS) was defined as the time from the date of study entry to the date of first documented tumor progression or death from any cause, whichever occurred first. If a patient did not have an event, PFS was censored at the last date of tumor assessment. For patients with measurable disease at baseline, progression was determined according to the RECIST 1.0 criteria. Only descriptive analysis done.
Time frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to 66 months
Median Time to Overall Survival (OS)
Overall Survival (OS) was defined as the time from the date of study entry to date of death due to any cause. If a death had not observed by the date of analysis, then OS was censored at the date of last contact. Distribution of OS was estimated using the Kaplan Meier method. The median OS along with 95% CI was presented.
Time frame: From Date of randomization up to approximately 66 months
Disease Control Rate (DCR)
Disease Control Rate (DCR) was defined as the proportion of patients whose best overall response was either: Complete Response (CR), Partial Response (PR) or Stable Disease (SD). Disease Control Rate was calculated only for patients with measurable disease at baseline and was summarized using descriptive statistics.
Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 66 months
Long-term Safety and Tolerability
The assessment of safety was based mainly on the frequency of AEs and on the number of laboratory values that fell outside of pre-determined ranges. Other safety data (e.g. ECG, vital signs) were considered as appropriate. Only descriptive analysis done.
Time frame: From Date of first dose up to approximately 66 months
This study was conducted in 7 study centers in Israel.
| Milestone | Everolimus + Letrozole |
|---|---|
| Started | 72 |
| Per protocol (pp) set | 72 |
| Safety set | 72 |
| Completed | 0 |
| Not completed | 72 |
| Withdrew: Adverse event | 9 |
| Withdrew: Disease progression | 48 |
| Withdrew: Death | 2 |
| Withdrew: Patient refused to complete study visit | 1 |
| Withdrew: Other protocol defined criteria | 12 |
Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. Only descriptive statistics.
| Percentage of Participants | Everolimus + Letrozole |
|---|---|
| Percentage of Participants With Overall Response Rate (ORR) | 37.2 |
Progression Free Survival (PFS) was defined as the time from the date of study entry to the date of first documented tumor progression or death from any cause, whichever occurred first. If a patient did not have an event, PFS was censored at the last date of tumor assessment. For patients with measurable disease at baseline, progression was determined according to the RECIST 1.0 criteria. Only descriptive analysis done.
| Months | Everolimus + Letrozole |
|---|---|
| Median Time to Progression-Free Survival (PFS) | 9.0 (0.2 to 59.6) |
Overall Survival (OS) was defined as the time from the date of study entry to date of death due to any cause. If a death had not observed by the date of analysis, then OS was censored at the date of last contact. Distribution of OS was estimated using the Kaplan Meier method. The median OS along with 95% CI was presented.
| Months | Everolimus + Letrozole |
|---|---|
| Median Time to Overall Survival (OS) | 22.3 (0.2 to 65.0) |
Disease Control Rate (DCR) was defined as the proportion of patients whose best overall response was either: Complete Response (CR), Partial Response (PR) or Stable Disease (SD). Disease Control Rate was calculated only for patients with measurable disease at baseline and was summarized using descriptive statistics.
| Percentage of Participants | Everolimus + Letrozole |
|---|---|
| Disease Control Rate (DCR) | 85.7 (74.6 to 93.3) |
The assessment of safety was based mainly on the frequency of AEs and on the number of laboratory values that fell outside of pre-determined ranges. Other safety data (e.g. ECG, vital signs) were considered as appropriate. Only descriptive analysis done.
| Participants | Everolimus + Letrozole |
|---|---|
| AEs - All | 72 |
| AEs - Grade 3 | 39 |
| AEs - Grade 4 | 7 |
On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of 2002 days (treatment duration ranged from 1 to 1974 days). Deaths post treatment survival follow up were collected after the on- treatment period, up to approximately 2092 days. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.
| Participants | Everolimus + Letrozole |
|---|---|
| On-treatment deaths | 2 |
| Post-treatment deaths | 50 |
| All deaths | 52 |
Collected over Adverse Events were collected from First Patient First Treatment (FPFT) up to 28 days after study drug discontinuation, for a maximum duration of 2002 days (treatment duration ranged from 1 to 1974 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus + Letrozole | 2/72 (2.8%) | 26/72 (36.1%) | 71/72 (98.6%) |
| Event | Everolimus + Letrozole |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/72 |
| VomitingGastrointestinal disorders | 3/72 |
| PyrexiaGeneral disorders | 3/72 |
| Disease progressionGeneral disorders | 2/72 |
| CellulitisInfections and infestations | 2/72 |
| Acute kidney injuryRenal and urinary disorders | 2/72 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/72 |
| Cardiac arrestCardiac disorders | 1/72 |
| Cardiac failure congestiveCardiac disorders | 1/72 |
| HypercalcaemiaEndocrine disorders | 1/72 |
| Event | Everolimus + Letrozole |
|---|---|
| FatigueGeneral disorders | 49/72 |
| StomatitisGastrointestinal disorders | 27/72 |
| Decreased appetiteMetabolism and nutrition disorders | 24/72 |
| Mucosal inflammationGeneral disorders | 23/72 |
| CoughRespiratory, thoracic and mediastinal disorders | 23/72 |
| HeadacheNervous system disorders | 22/72 |
| RashSkin and subcutaneous tissue disorders | 22/72 |
| AnaemiaBlood and lymphatic system disorders | 21/72 |
| DiarrhoeaGastrointestinal disorders | 21/72 |
| Weight decreasedInvestigations | 21/72 |
| Age, Continuous(Years) | Everolimus + Letrozole |
|---|---|
| Mean | 61.7 ± 9.5 |
| Sex: Female, Male(Participants) | Everolimus + Letrozole |
|---|---|
| Female | 72 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Everolimus + Letrozole |
|---|---|
| Caucasian | 72 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Aug 2011 to primary completion in Nov 2012, 15 months.
Results were first posted in Mar 2021, 8 years 4 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 15 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Everolimus · Letrozole